The Choriocarcinoma (Gestational Trophoblastic Neoplasia) drugs in development market research report provides comprehensive information on the therapeutics under development for Choriocarcinoma (Gestational Trophoblastic Neoplasia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Choriocarcinoma (Gestational Trophoblastic Neoplasia). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) by four companies/universities/institutes. The top development phase for Choriocarcinoma (Gestational Trophoblastic Neoplasia) is phase i with three drugs in that stage. The Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline products market are: Jiangsu Hengrui Medicine, Merck and GSK.
The key targets in the Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline products market include Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, and Vascular Endothelial Growth Factor Receptor 2.
The key mechanisms of action in the Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline product include Programmed Cell Death Protein 1 Antagonist with three drugs in Phase II. The Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline products include five routes of administration with the top ROA being Intravenous and two key molecule types in the Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline products market including Monoclonal Antibody, and Small Molecule.
Choriocarcinoma (Gestational Trophoblastic Neoplasia) overview
Gestational trophoblastic disease (GTD) is a group of rare tumors that develop during the early stages of pregnancy. Most GTD tumors are benign (noncancerous), but some may turn into malignant (cancerous). GTD is categorized into hydatidiform moles and gestational trophoblastic neoplasia (GTN). Risk factors include age younger than 20 or older than 35, previous molar pregnancy, and history of miscarriage. Symptoms include bleeding or discharge not related to menstruation, larger than usual uterus in pregnancy, and pain or mass in the pelvic area. It can be diagnosed through internal pelvic examination, pap test, transvaginal ultrasound, and urinalysis. Methods of treatment include surgery, chemotherapy, hysterectomy, and radiation therapy.
For a complete picture of Choriocarcinoma (Gestational Trophoblastic Neoplasia)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
